1. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021) Authors: Macaluso, F.S.; Cappello, M.; Busacca, A.; Fries, W.; Viola, A.; Costantino, G.; Magnano, A.; Vinci, E.; Ferracane, C.; Privitera, A.C.; Piccillo, G.; Belluardo, N.; Giangreco, E.; Romano, C.; Citrano, M.; Graziano, F.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Scrivo, B. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Issue 3 (4th July 2016) Authors: Renna, S.; Orlando, E.; Macaluso, F. S.; Maida, M.; Affronti, M.; Giunta, M.; Sapienza, C.; Rizzuto, G.; Orlando, R.; Dimarco, M.; Cottone, M.; Orlando, A. Journal: Alimentary pharmacology & therapeutics Issue: Volume 44:Issue 3(2016) Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Letter: switching from one to another anti‐tumour necrosis factor alpha agent, and the risks of an overlap of exposure. Issue 9 (May 2016) Authors: Macaluso, F. S.; Criscuoli, V.; Orlando, E.; Rizzuto, G.; Renna, S.; Cottone, M.; Orlando, A. Journal: Alimentary pharmacology & therapeutics Issue: Volume 43:Issue 9(2016) Page Start: 1019 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab. Issue 7 (7th March 2018) Authors: Macaluso, F. S.; Orlando, R.; Renna, S.; Sapienza, C.; Ventimiglia, M.; Rizzuto, G.; Cottone, M.; Orlando, A. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 7(2018) Page Start: 1040 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020) Authors: Macaluso, F.S.; Ventimiglia, M.; Fries, W.; Viola, A.; Cappello, M.; Scrivo, B.; Magnano, A.; Pluchino, D.; Camilleri, S.; Garufi, S.; Di Mitri, R.; Mocciaro, F.; Magrì, G.; Ferracane, C.; Citrano, M.; Graziano, F.; Bertolami, C.; Renna, S.; Orlando, R.; Rizzuto, G. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OC.06.2: The Sicilian Network of Biological Therapy in Inflammatory Bowel Disease: Preliminary Data from a Prospective Study on Efficacy and Safety. (15th March 2017) Authors: Orlando, A.; Fries, W.; Privitera, A.; Cappello, M.; Siringo, S.; Inserra, G.; Magnano, A.; Di Mitri, R.; Belluardo, N.; Scarpulla, G.; Magrì, G.; Trovatello, A.; Carroccio, A.; Genova, S.; Calandruccio, G.; Vassallo, R.; Romano, C.; Magazzù, G.; Citrano, M.; Accomando, S. Journal: Digestive and liver disease Issue: Volume 49(2017)Supplement 2 Page Start: e91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OC.06.4: The Addition of an Immunosuppressant is an Effective Optimization Strategy after Loss of Response to Anti-Tnf Alpha Monotherapy in Patients with Inflammatory Bowel Disease: A Two-Year Experience. (15th March 2017) Authors: Macaluso, F.S.; Sapienza, C.; Ventimiglia, M.; Renna, S.; Rizzuto, G.; Orlando, R.; Affronti, M.; Orlando, E.; Cottone, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 49(2017)Supplement 2 Page Start: e92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OC.06.5: Mycophenolate Mofetil is a Valid Option in Patients with Inflammatory Bowel Disease Resistant to TNF-Alpha Inhibitors and Conventional Immunosuppressants. (15th March 2017) Authors: Macaluso, F.S.; Maida, M.; Renna, S.; Orlando, E.; Affronti, M.; Sapienza, C.; Dimarco, M.; Orlando, R.; Rizzuto, G.; Cottone, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 49(2017)Supplement 2 Page Start: e92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OC.09.8 BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. (September 2021) Authors: Grova, M.; Crispino, F.; Maida, M.; Renna, S.; Mocciaro, F.; Casà, A.; Rizzuto, G.; Di Mitri, R.; Macaluso, F.S.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2. (1st October 2020) Authors: Macaluso, F.S.; Fries, W.; Viola, A.; Centritto, A.; Cappello, M.; Giuffrida, E.; Privitera, A.C.; Piccillo, G.; Magnano, A.; Vinci, E.; Vassallo, R.; Trovatello, A.; Belluardo, N.; Giangreco, E.; Camilleri, S.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Renna, S.; Orlando, R. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗